TIGIT and neoplasm: Treatment with the mIgG1 backbone anti-TIGIT mAb did not drive antitumor activity in the CT26 syngeneic murine tumor model (Figure 2G), despite showing robust ability to block the inhibitory TIGIT signaling axis (Figure 2F).